177 related articles for article (PubMed ID: 3594714)
1. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman EH; Ferrans VJ; Bhat HB; Witiak DT
Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
3. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Herman EH; Ferrans VJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
[TBL] [Abstract][Full Text] [Related]
4. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
6. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
[TBL] [Abstract][Full Text] [Related]
7. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
8. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
Herman EH; Ferrans VJ
Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
[TBL] [Abstract][Full Text] [Related]
9. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268
[TBL] [Abstract][Full Text] [Related]
11. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
12. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Dardir M; Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1989; 23(5):269-75. PubMed ID: 2495862
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Herman EH; el-Hage A; Ferrans VJ
Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
15. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
16. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
Herman EH; Ferrans VJ; Jordan W; Ardalan B
Res Commun Chem Pathol Pharmacol; 1981 Jan; 31(1):85-97. PubMed ID: 6789416
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Herman EH; el-Hage AN; Creighton AM; Witiak DT; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):39-55. PubMed ID: 3922023
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds.
Herman EH; Ferrans VJ
Cancer Treat Rev; 1987 Dec; 14(3-4):225-9. PubMed ID: 3125968
[No Abstract] [Full Text] [Related]
19. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
